wilate®

High-purity, human von Willebrand factor/coagulation factor VIII complex concentrate

Contains von Willebrand factor and factor VIII in a 1:1 activity ratio1.

Indication 

Indicated for the prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) alone is ineffective or contra-indicated, and for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

Presentation 

Available in vials of: 500 IU and 1000 IU.

Key features of wilate®
  • 14 years of clinical experience;
  • Proven safety and efficacy in the treatment and prevention of bleeding, including surgical prophylaxis, for types 1, 2 and 3 von Willebrand disease (VWD) and haemophilia A1;
  • No accumulation of FVIII after repeated dosing2 and no reports of thrombotic complications2,3;
  • Two independent virus-inactivation steps1.
References 

1. wilate® Summary of Product Characteristics.
2. Srivastava A et al. Haemophilia 2017; 23:264-72.
3. Berntorp E et al. Haemophilia 2009; 15:122-30.

You are now on Octapharma’s global website. Please select your country from the menu at the top of this page to access more detailed country-specific information or to contact your local Octapharma team.